Switch theme
Sign up to access all valuation multiples
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
2011
16
Last FY Revenue n/a
Last FY EBITDA -$25.3M
$2.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Skye Bioscience achieved revenue of n/a and an EBITDA of -$25.3M.
Skye Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Skye Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$25.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$37.4M | XXX | -$36.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$34.6M | XXX | -$26.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Skye Bioscience's stock price is $2.
Skye Bioscience has current market cap of $61.3M, and EV of $2.5M.
See Skye Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5M | $61.3M | XXX | XXX | XXX | XXX | $-0.93 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Skye Bioscience has market cap of $61.3M and EV of $2.5M.
Skye Bioscience's trades at n/a EV/Revenue multiple, and -0.1x EV/EBITDA.
Equity research analysts estimate Skye Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Skye Bioscience has a P/E ratio of -1.8x.
See valuation multiples for Skye Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61.3M | XXX | $61.3M | XXX | XXX | XXX |
| EV (current) | $2.5M | XXX | $2.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -2.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSkye Bioscience's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.3M for the same period.
Skye Bioscience's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Skye Bioscience's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Skye Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Skye Bioscience acquired XXX companies to date.
Last acquisition by Skye Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Skye Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Skye Bioscience founded? | Skye Bioscience was founded in 2011. |
| Where is Skye Bioscience headquartered? | Skye Bioscience is headquartered in United States of America. |
| How many employees does Skye Bioscience have? | As of today, Skye Bioscience has 16 employees. |
| Who is the CEO of Skye Bioscience? | Skye Bioscience's CEO is Mr. Punit Dhillon. |
| Is Skye Bioscience publicy listed? | Yes, Skye Bioscience is a public company listed on NAS. |
| What is the stock symbol of Skye Bioscience? | Skye Bioscience trades under SKYE ticker. |
| When did Skye Bioscience go public? | Skye Bioscience went public in 2014. |
| Who are competitors of Skye Bioscience? | Similar companies to Skye Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Skye Bioscience? | Skye Bioscience's current market cap is $61.3M |
| Is Skye Bioscience profitable? | Yes, Skye Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
